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Abstract
Background: Intramyocardial injection of skeletal myoblasts (SMB) has been shown to be a promising strategy for treating
post-infarction chronic heart failure. However, insufficient therapeutic benefit and occurrence of ventricular arrhythmias are
concerns. We hypothesised that the use of a retrograde intracoronary route for SMB-delivery might favourably alter the
behaviour of the grafted SMB, consequently modulating the therapeutic effects and arrhythmogenicity.
Methods and Results: Three weeks after coronary artery ligation in female wild-type rats, 56106 GFP-expressing SMB or PBS
only (control) were injected via either the intramyocardial or retrograde intracoronary routes. Injection of SMB via either
route similarly improved cardiac performance and physical activity, associated with reduced cardiomyocyte-hypertrophy
and fibrosis. Grafted SMB via either route were only present in low numbers in the myocardium, analysed by real-time PCR
for the Y-chromosome specific gene, Sry. Cardiomyogenic differentiation of grafted SMB was extremely rare. Continuous
ECG monitoring by telemetry revealed that only intramyocardial injection of SMB produced spontaneous ventricular
tachycardia up to 14 days, associated with local myocardial heterogeneity generated by clusters of injected SMB and
accumulated inflammatory cells. A small number of ventricular premature contractions with latent ventricular tachycardia
were detected in the late-phase of SMB injection regardless of the injection-route.
Conclusion: Retrograde intracoronary injection of SMB provided significant therapeutic benefits with attenuated early-
phase arrhythmogenicity in treating ischaemic cardiomyopathy, indicating the promising utility of this route for SMB-
delivery. Late-phase arrhythmogenicity remains a concern, regardless of the delivery route.
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Introduction
Both experimental and initial clinical studies have shown that
transplantation of skeletal myoblasts (SMB) into the heart is a
promising treatment for post myocardial infarction (MI) chronic
heart failure (HF). However, a recent large-scale randomised
clinical study has suggested that the therapeutic efficacy of this
strategy may not be as substantial as expected when conjugated
with coronary artery bypass surgery [1,2]. In addition, the risk of
arrhythmia occurrence associated with this treatment is not fully
understood [1–4]. It is therefore essential to explore a strategy to
amplify the therapeutic benefits and reduce the arrhythmogenicity
for the future success of SMB transplantation.
Of note, almost all experimental and clinical studies to date
have utilised intramyocardial (IM) injection for SMB delivery into
the heart. However, this method is known to have disadvantages
including formation of islet-like cell-clusters and induction of
myocardial damage and disruption [5,6]. We hypothesised that
these adverse events may be a cause of the insufficient therapeutic
benefits and arrhythmia occurrence following the treatment. In
contrast, intracoronary (IC) injection has been reported to enable
widespread dissemination of donor cells with less myocardial
damage [6–8]. Although the antegrade IC route is frequently used
in clinical trials of bone marrow cell injection into the heart [9],
this route is likely to carry a high risk of coronary embolism when
SMB are injected because of their larger cell-size [7]. On the other
hand, retrograde IC injection (injection into the cardiac veins) has
been demonstrated to achieve widespread dissemination of donor
cells in the heart with little risk of coronary embolism [8]. Cells
disseminated cells in such a gentle manner are more likely to
survive and maintain important properties such as differentiation,
integration and secretion, consequently leading to an enhanced
therapeutic outcome and reduced arrhythmogenicity.
In this study, we therefore examined the efficiency and pattern
of cell-distribution, behaviour of the grafted cells, therapeutic
efficacy and arrhythmogenicity after retrograde IC injection of
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SMB into the post-MI chronically failing heart, in comparison
with direct IM injection.
Methods
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). All surgical
procedures and evaluations, particularly cardiac function mea-
surement by echocardiography, were carried out in a blinded
manner.
Collection, culture and characterisation of SMB
Primary SMB were isolated from male GFP-transgenic Sprague-
Dawley (SD) rats (200–250 g, Rat Research & Resource Center) by
the single fibre method (n=10) [10]. Briefly, the extensor digitorum
longus was digested with 0.2% type I collagenase (Sigma) and
individual, intact myofibres were then placed onto a culture plate,
from which SMB migrated and proliferated in growth medium
containing 20% foetal calf serum, 10% horse serum, 0.5% chick
embryo extract and 5 ng/ml basic fibroblast growth factor
(Molecular Probes) in DMEM with 1% penicillin/streptomycin.
Myogenic differentiation ability of the cells was confirmed to be the
same as that of SMB derived from wild-type rats by culturing in low
serum (2% horse serum) medium [10].
Generation of post-MI chronic HF and SMB injection
Female wild-type SD rats (150–200 g, Harlan) underwent
permanent left coronary artery (LCA) ligation under mechanical
ventilation and 1.5% isoflurane inhalation (n=190) [6]. At 3 weeks
after LCA ligation, cell injection via either the direct IM or
retrograde IC route was carried out (n=165) [6]. For direct IM
injection, a total of 56106 SMB suspended in 100 ml of PBS (SMB-
IM group, n=48) or 100 ml of PBS (PBS-IM group, n=32) was
injected into two sites of the peri-infarct area using a 31-gauge
needle. For retrograde IC injection, 56106 SMB suspended in
500 ml of PBS (SMB-IC group, n=49) or 500 ml of PBS (PBS-IC
group, n=36) were slowly injected with a constant pressure over 30
seconds through a 24-gauge catheter (BD Biosciences) inserted into
the left cardiac vein. The stem of left cardiac vein was snared from
the start of injection till 30 seconds after the completion of injection.
Assessment of cardiac function and structure
Echocardiography (Sequoia 512 and 15-MHz probe, Siemens
Medical) was carried out under 1.5% isoflurane inhalation via a
nose corn at one day before, and days 3, 7, 28 and 84 after
injection (n=10 in each group at each time point) [6]. Left
ventricular ejection fraction (LVEF) was assessed by 2-dimensional
mode at the mid-papillary level, and LV diastolic/systolic
dimensions (LVDd/LVDs) were assessed by M-mode [11].
Transmitral E/A flow ratio was assessed by spectral Doppler
traces [12].
Assessment of spontaneous arrhythmia and physical
activity by telemetry
Spontaneous arrhythmia occurrence and physical activity were
assessed by telemetry (Data Sciences International) [13,14]. A
transmitter and two electrodes were implanted 1 day before
injection. ECG and signal strength were continuously monitored
at day 1, 3, 7, 14, 28, 42, 56 and 84 (n=7 in the PBS-IM and PBS-
IC groups and n=8 in the SMB-IM and SMB-IC groups). The
hourly number of ventricular premature contractions (VPC),
calculated as an average over 24-hours recording, and frequency
of VT were assessed.
The signal strength, which is changed by physical movement of
the rat, was monitored at 64 Hz as an indicator of physical activity
[14]. The average of 24 hours recording was calculated using
software (DSI Dataquest A.R.T. TM Analysis, Data Science
International). Low counts of change in signal strength indicate
reduced physical activity.
Arrhythmia induction by isoproterenol administration
Isolated hearts were perfused at 100 cm H2O with modified
Krebs-Henseleit buffer (144.9 mM Na+, 126.3 mM Cl2, 4.9 mM
K+, 25.0 mM HCO3
2, 1.2 mM SO4
2, 1.2 mM Mg2+, 1.25 mM
Ca2+, 1.2 mM PO4
32 and 10.0 mM glucose; gassed with 95%
O2+5% CO2 at 37uC) using a Langendorff apparatus at day 84
(n=3 in the PBS-IM and PBS-IC groups and n=6 in the SMB-IM
and SMB-IC groups) [7]. After 20-minutes stabilisation,
161027 M isoproterenol (Sigma) was administered continuously
via the perfusate for 10 minutes [15] with the ECG being
monitored for the analysis using MP35 and Biopac Systems
(Linton Instrumentation).
Histological analysis
Hearts were collected at day 3 and 28, fixed by 4%
paraformaldehyde perfusion, cut transversely and frozen (n=5 in
each group). Fifteen-mm cryosections were labelled with polyclonal
anti-GFP (1:1000 dilution, Molecular Probes) [6], monoclonal
anti-CD45 (1:250 dilution, BD Pharmingen) or monoclonal anti-
connexin(Cx)43 (1:500 dilution, Chemicon) [16] antibodies. The
labelled sections were visualised by either HRP-based kit (DAKO)
with haematoxylin counterstaining or by immunoconfocal micros-
copy (LSM510, Zeiss).
To evaluate myocardial collagen deposition, cryosections from
day-28 hearts were stained with 0.1% Picrosirus red (n=5 in each
group) [17]. The collagen volume fraction was semi-quantitatively
assessed using NIH image-analysis software (randomly selected 20
high-power fields per one heart). To evaluate myocardial capillary
density, cryosections at day 28 were labelled with polyclonal anti-
von Willebrand Factor (vWF) antibody (1:250 dilution, DAKO)
and assessed using confocal microscopy (n=5 in each group)
[18,19]. The number of capillary vessels, which were positively
stained and had 5–10 mm in diameter, was counted in the peri-
infarct area (randomly selected 16 high-power fields per one heart)
and was averaged to express a capillary density (per 1 mm2).
Quantitative analysis of the graft survival by real-time
PCR for Sry
The presence of male grafted cells in the female heart was
quantitatively assessed to define graft survival by using real-time
PCR (ABI PRISM 7700 and TaqMan chemistry) for the Y-
chromosome specific Sry gene in DNA extracted from the entire
LV walls. Sry levels were normalised to the DNA amount using the
autosomal single copy gene, oesteopontin [6]. Data were analysed
using the Ct method [20].
A standard curve was prepared from serial dilution series (1, 1/
3, 1/9, 1/27, 1/81 and 1/243) of the DNA extracted from a
mixture of male SMB (56106) and female entire LV walls at 21
days after LCA ligation (n=3). The number of surviving grafted
cells at day 3, 7, 28 and 84 (n=5 in the SMB-IM and SMB-IC
groups at each time point) was estimated by correcting relative Sry
expression using this standard curve.
Cell area planimetry of isolated native cardiomyocytes
At day 28, cardiomyocytes were isolated from the heart by
enzymatic dissociation (n=6 in the normal female SD rats, PBS-
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IM, SMB-IM and SMB-IC group) [21]. After perfusion with
collagenase (1.3 mg/mL, Worthington Biochemical) and hyal-
uronidase (0.6 mg/mL, Sigma), the LV tissue was cut into small
pieces and further dissociated to yield a single-cell suspension. The
projected 2-dimensional area for each GFP-negative rod-shape
cardiomyocyte was assessed by NIH image-analysis software. The
cell number examined was 221 in the normal, 225 in the PBS-IM,
328 in the SMB-IM and 336 in the SMB-IC groups.
Statistical analysis
All values are expressed as Mean6SEM. HR, LVDd/Ds, peak
E/A, LVEF, physical activity and VPC number were compared
using 2-way ANOVA followed by Bonferroni’s test for individual
significant difference. Collagen volume, capillary density and
cardiomyocyte-area were compared using 1-way ANOVA fol-
lowed by Bonferroni’s test. Frequency of spontaneous and induced
VT was compared using chi square test. HR and VPC number
under isoproterenol were compared using paired-t test. p,0.05
was considered to be statistically significant.
Results
Mortality after LCA ligation and cell injection
Mortality after LCA ligation before cell injection was 11.6%
(21/190) in total. Among the surviving rats, 4 (2.6%) were
excluded due to their LVEF being more than 40% one day before
cell injection. Mortality after cell injection was similar in all
groups; 6.3% (2/32) in the PBS-IM, 8.3% (3/36) in the PBS-IC,
8.3% (4/48) in the SMB-IM, 8.2% (4/49) in the SMB-IC groups.
Improved cardiac function and physical activity after cell
injection
Cardiac function and dimensions were serially assessed using
echocardiography. Baseline values (normal rats) were 363618 bpm
for HR, 73.961.8% for LVEF, 6.760.3/3.860.3 mm for LVDd/
LVDs and 1.760.2 for peak E/A (n=10). At 20 days after LCA
ligation, reduced LVEF (32.960.2%, p,0.001), enlarged LVDd/
LVDs (9.060.1/7.760.2 mm, p,0.001) and reduced E/A
(1.260.1 p,0.01) were observed (n=165).
Figure 1. Cardiac function and physical activity. A: LVEF, assessed by 2-dimensional mode echocardiography, was significantly greater in the
SMB-IM and SMB-IC groups than that in the PBS-IM and PBS-IC groups, respectively, at day 7, 28 and 84. n= 10 in each group at each time point. 21;
one day before injection. B: Physical activity in the SMB-IM and SMB-IC groups was greater than that in the PBS-IM and PBS-IC groups at day 28 and
84. n= 7 in the PBS-IM and PBS-IC groups; n= 8 in the SMB-IM and SMB-IC groups at each time point. *p,0.05 vs. the PBS-IM group; {p,0.05 vs. the
PBS-IC group at each time point.
doi:10.1371/journal.pone.0003071.g001
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LVEF after PBS injection via either route was not significantly
changed throughout the experimental period (Figure 1A) but was
significantly greater following injection of SMB via either route
between day 7 and 84 (p,0.001). Compared to before injection
(33.460.6% in the SMB-IM and 34.560.6% in the SMB-IC
groups, respectively), LVEF was improved by day 7 after IM or IC
SMB injection (43.660.7% and 43.960.7%, respectively,
p,0.05). SMB injection via either route resulted in lower HR,
smaller LVDs and greater E/A at day 28, but not at day 84,
compared to PBS injection (Table 1).
All the groups showed an improvement in physical activity by
day 7, though this was not statistically significant, presumably due
to recovery from the surgical stress. Whereas physical activity did
not increase day 7 after PBS injection via either route, injection of
SMB via either route improved physical activity by day 28
(Figure 1B). Improved activity after SMB injection continued until
day 84.
Occurrence of spontaneous arrhythmias following SMB
injection
Spontaneous arrhythmias were assessed by continuous ECG
monitoring using telemetry. Arrhythmias rarely occurred 1 day
before cell transplantation (20 days after permanent LCA ligation)
or till 84 days after PBS injection via either route (Figure 2A). Of
note, IM injection of SMB caused frequent VPC ($40/hour)
within 24 hours after injection, which lasted until day 14 with a
peak at day 3 (124675/hour). In addition, only IM injection of
SMB caused VT in 50% of animals at day 3 and day 7 (Figure 2B),
whereas there was no animal showing VT in the other groups at
the same time points. Subsequently, the number of VPC gradually
decreased, although a small number of VPC ($5/hour)
persistently remained until day 84. In contrast, in the SMB-IC
groups, VPC or VT rarely occurred until day 7, whereas a small
number of VPC occurred at day 14 and persisted to day 84. No
spontaneous VT was observed at day 84 in any group.
Isoproterenol-induced arrhythmia
Isoproterenol was administered to the hearts under Langendorff
perfusion in order to uncover latent arrhythmogenicity. Isopro-
terenol administration increased HR in all groups (p,0.05,
Table 2). The frequency of VPC was increased by isoproterenol
administration in the hearts after SMB injection via either route
(p,0.05), while VPC number was not significantly increased in the
hearts after PBS injection. Of note, VT was induced in 83.3%
hearts after SMB injection via either route (Figure 2C and D),
while no VT was induced in the hearts after PBS injection.
Behaviour of grafted cells in the myocardium
Grafted cells were identified in the myocardium by labelling for
GFP. At day 3 after IM injection of SMB, islet-like GFP-positive
cell-clusters were formed which disrupted the myocardial structure
in the peri-infarct area (Figure 3A). These cell-clusters consisted of
grafted GFP-positive cells and native GFP-negative CD45-positive
cells (Figure 3B and C). Formation of Cx43-gap junctions was not
evident between the grafted cells and surrounding native
cardiomyocytes (Figure 3D). At day 28 after IM injection of
SMB, the size of the GFP-positive grafts had generally decreased
(Figure 3E) and the majority of the GFP-positive cells appeared to
be isolated from the native cardiomyocytes (Figure 3F).
In contrast, at day 3 after retrograde IC injection of SMB,
myocardial structure was not disrupted by GFP-positive cell-
clusters (Figure 3G) and GFP-positive cells were disseminated
among the native cardiomyocytes in peri-infarct areas (Figure 3H).
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The degree of CD45-positive cell-accumulation surrounding the
GFP-positive cells was lower than that after IM injection of SMB
(Figure 3I). Although the grafted cells in the peri-infarct area
appeared to have a direct contact with native cardiomyocytes,
formation of Cx43-gap junctions between these cells was not
evident (Figure 3J). There was no observation suggesting coronary
embolism after retrograde IC injection of SMB. At day 28 after
retrograde IC injection, GFP-positive cells were detected with an
elongated myotube-like morphology (Figure 3K).
The frequency of GFP-positive cardiomyocyte-like cells derived
from transdifferentiation or fusion of donor SMB was extremely
low. Our thorough examination detected only one such cell after
retrograde IC injection of SMB (Figure 3L). This GFP-positive cell
with cardiomyocyte-morphology formed Cx43-gap junctions with
GFP-negative native cardiomyocytes.
Poor graft survival after SMB injection
In our model, male cells were injected into female hearts in
order to quantitatively analyse graft survival using real-time PCR
for the Y-chromosome specific gene, Sry. At day 3 after IM
injection of SMB, 6.762.36105 male cells (1465% of total
injected cells) were present in the LV, while 5.262.76105 cells
Figure 2. Spontaneous and induced occurrence of arrhythmias. A: The hourly number of spontaneous VPC was calculated as an average of
the VPC number detected over the 24-hour continuous ECG recording by telemetry. VPC were frequently detected at day 1 only in the SMB-IM group
with a peak at day 3. The VPC number in the SMB-IM group decreased by day 14, but a small number of VPC were persistent until day 84. In contrast,
in the SMB-IC group, VPC rarely occurred until day 7, while a small number of VPC were observed between day 14 and 84. Both the PBS-IM or PBS-IC
groups rarely showed VPC throughout the study. n= 7 in the PBS-IM and PBS-IC groups; n= 8 in the SMB-IM and SMB-IC groups at each time point.
*p,0.05 vs. the PBS-IM group; {p,0.05 vs. the PBS-IC group at each time point. B: Representative ECG of spontaneous VT in the SMB-IM group. C and
D: Representative ECGs of induced VT by isoproterenol administration under Langendorff isolated-heart perfusion in the SMB-IM (C) and SMB-IC
groups (D). Scale bar = 500 msec.
doi:10.1371/journal.pone.0003071.g002
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(1065%) existed at day 3 after retrograde IC injection of SMB
(Figure 4). The number of grafted cells present in the LV
decreased to 1.960.46105 cells (461%) or 2.061.06105 cells
(461%) by day 7 and further decreased to 0.260.16105 cells
(0.360.2%) or 0.260.16105 cells (0.360.2%) by day 28 after
direct IM or retrograde IC injection of SMB, respectively.
Changes in the native myocardium after SMB injection
Native (GFP-negative) cardiomyocytes, isolated by enzymatic
dissociation, were assessed for cell size. Cardiomyocytes after PBS
injection were significantly larger than those from uninfarcted,
normal animals (4,143668 mm2 vs. 3,074661 mm2, p,0.05,
Figure 5). This hypertrophy showed a significant, but not
complete, regression in the cardiomyocytes isolated after either
IM injection of SMB (3,657653 mm2) or retrograde IC injection
of SMB (3,690664 mm2, p,0.05).
Picrosirius red staining demonstrated that a marked collagen
deposition occurred in the extracellular space in the peri-infarct
areas after PBS injection with a collagen volume fraction of
approximately 23% (Figure 6A and C). Fibrosis was comparably
and significantly reduced in the myocardium after SMB injection
via IM (15.660.6%) or retrograde IC (14.160.5%) route. Fibrosis
was also observed in infarct-remote areas after PBS injection with
the collagen volume fraction reaching approximately 15%
(Figure 6B and D). This was also significantly decreased after
SMB injection via IM (12.760.4%) or retrograde IC (11.361.2%)
route. Capillary density, which was assessed in peri-infarct areas of
vWF-labelled samples (Figure 6E), was not significantly different
after SMB injection (710613/mm2 in the SMB-IM group and
711613/mm2 in the SMB-IC group), compared to the corre-
sponding control group (685624/mm2 in the PBS-IM group and
660636/mm2 in the PBS-IC group, Figure 6F).
Discussion
In the present study, we demonstrate that retrograde IC
injection of SMB improves cardiac function of post-MI chronic
HF. The therapeutic benefits were no less than that induced by IM
injection of the same number of SMB. Cell-distribution was
markedly different between IM and retrograde IC injection, but
overall graft survival was very similar. Interestingly, we observed
clear differences in the occurrence of arrhythmias dependent on
the cell-delivery route used. Following IM injection of SMB, two
different, time-dependent types of arrhythmia were seen; early-
phase frequent VPC with spontaneous VT and following late-
phase less-frequent VPC with latent VT. In contrast, after
retrograde IC injection of SMB, such early-phase VPC or VT
were absent. Regardless of the delivery-route, SMB injection into
the post-MI heart reduced hypertrophy of native cardiomyocytes
and decreased collagen deposition in both peri-infarct and infarct-
remote areas, but did not affect vascular formation. Cardiomyo-
genic trans-differentiation of the grafted SMB or fusion of the
grafted SMB with the native cardiomyocytes was only very rarely
detected, suggesting an important role of paracrine effects in the
observed therapeutic benefits of SMB transplantation.
The pattern of SMB-distribution was radically different
between IM and retrograde IC injection. IM injection formed
islet-like clusters of the grafted cells accompanied by myocardial
inflammation, while retrograde IC injection achieved widespread
SMB dissemination with little myocardial damage. Nevertheless,
survival of the grafted cells, recovery of cardiac function, or
improvement of physical activity after retrograde IC injection of
SMB was, contrary to our expectation, not significantly greater
than those after direct IM injection in the setting of our model.
However, SMB transplantation via retrograde IC injection is, as
compared to IM injection, likely to have greater potential to
achieve further augmentation of the therapeutic efficacy by
refining the injection protocol. Increasing injection pressure or
extending incubation time after injection will enhance the
efficiency of trans-endothelial migration of the grafted cells into
the myocardial interstitium, which is considered to be a limiting
process for successful cell-engraftment after retrograde IC
injection but is not relevant to IM injection. In addition, the
number of cells to be injected could be safely increased in
retrograde IC injection, whereas increasing cell number in IM
injection carries the risk of exacerbating inflammation and early-
phase arrhythmogenicity. These improvements of the protocol for
retrograde IC injection will be able to enhance the overall graft
size and consequent therapeutic effects, though further investiga-
tions are needed to confirm this. Experiments using a large
animal model would be appropriate to determine the optimal
protocol of retrograde IC injection of SMB in clinical settings. In
addition, more importantly, our study here demonstrated that
retrograde IC injection dramatically attenuated arrhythmia
occurrence in the early phase after injection, compared to IM
injection. In the clinical arena, retrograde IC injection can be
safely carried out by a balloon catheter percutaneously inserted
into the cardiac veins [22]. This will be advantageous over the
direct IM injection which requires either open-chest surgery or
highly-specialised equipment such as the NOGA system [4].
Taking all this information into consideration, we propose that
retrograde IC injection could be a more advantageous route for
SMB transplantation for treating post-MI chronic HF compared
to direct IM injection.
Table 2. Isoproterenol-induced arrhythmias.
Heart rate (bpm) Number of VPC (/hour) Samples showing VT (%)
Baseline Isoproterenol Baseline Isoproterenol Baseline Isoproterenol
PBS-IM 235629 375617* 262 462 0.0% 0.0%
PBS-IC 260612 353618* 060 16613 0.0% 0.0%
SMB-IM 26368 380621* 2869 87643* 0.0% 83.3%{
SMB-IC 224628 367624* 462 65623* 0.0% 83.3%{
n=7 in the PBS-IM and PBS-IC groups; n= 8 in the SMB-IM and SMB-IC groups.
*p,0.05 vs. baseline value.
{p,0.05 vs. the PBS-IM group.
{p,0.05 vs. the PBS-IC group.
doi:10.1371/journal.pone.0003071.t002
Cell-Delivery into the Heart
PLoS ONE | www.plosone.org 6 August 2008 | Volume 3 | Issue 8 | e3071
Figure 3. Behaviour of grafted cells in the myocardium. A: Immunohistolabelling for GFP with haematoxylin counterstaining detected GFP-
positive (brown) cell-clusters disrupting the myocardial structure in the SMB-IM group at day 3. B: In higher magnification of the outlined area in A,
the cell-clusters consisted of GFP-positive and negative cells. C: Confocal micrograph (green for GFP, red for CD45, blue for nuclei) in the SMB-IM
group at day 3 shows that GFP-positive cells are surrounded by a number of GFP-negative CD45-positive cells. D: Confocal micrograph (green for
GFP, red for Cx43) in the SMB-IM group at day 3 shows the lack of gap junctions between GFP-positive cells and adjacent GFP-negative
cardiomyocytes. E: At day 28 in the SMB-IM group, a small number of GFP-positive cells are surrounded by fibrous tissues. F: Confocal micrograph
(green for GFP, red for Cx43) in the SMB-IM group at day 28 shows no gap-junctions between the GFP-positive cells and adjacent GFP-negative
cardiomyocytes. G: At day 3 in the SMB-IC group, GFP-positive cells were widely disseminated without disrupting the myocardial structure. Please
note that it is difficult to see individual disseminated cells in the low magnification image. H: Higher magnification of the outlined areas in G shows
GFP-positive cells with less myocardial damage and inflammation, compared to the SMB-IM group. I: Confocal micrograph (green for GFP, red for
CD45, blue for nuclei) shows less accumulation of CD45-positive cells surrounding the GFP-positive cells compared to the SMB-IM group. J: Confocal
micrograph (green for GFP, red for Cx43) in the SMB-IC group at day 3 does not show any gap-junctions between the GFP-positive cells and
cardiomyocytes. K: At day 28 in the SMB-IC group, a small number of GFP-positive cells were detected. L: Confocal micrograph (green for GFP, red for
Cx43) shows the only example of a GFP-positive cell with cardiomyocyte-like morphology forming gap-junctions with a native cardiomyocyte
(arrows) in the SMB-IC group. Scale bar = 500 mm in A and F, 50 mm in B–E and G–L.
doi:10.1371/journal.pone.0003071.g003
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The present study provides important information to determine
the mechanism by which SMB injection improves the function of
post-MI chronically failing myocardium. Consistent with previous
reports [5], we observed extremely rare events of cardiomyogenic
differentiation of the grafted SMB or fusion with the native
cardiomyocytes regardless of the cell-delivery route. Such an
extremely low frequent event is unlikely to contribute for global
cardiac function or arrhythmia occurrence regardless of its origin.
Instead, there was significant regression of hypertrophy of the
cardiomyocytes and reduction of pathological fibrosis not only in the
peri-infarct but also in the infarct-remote areas, suggesting that
paracrine effects may play an important role in the therapeutic
benefits of SMB transplantation. Interestingly, unlike acute MI [10],
neovascularisation was not enhanced by SMB injection in the present
study targeting post-MI chronic HF, indicating that the paracrine
effects may be affected by the condition of the native myocardium.
Although Bonaros et al [23,24] suggested angiogenic effects of SMB
on post-infarction chronically failing heart, cell-injection timing and
MI size are different from the present study. Differently-diseased
myocardium could differently respond to the same paracrine stimuli,
or might differently modulate the secretion from the grafted SMB.
LV dimensions and peak E/A ratio at 84 days following SMB
injection via either route was not significantly greater than those
following PBS injection, though LVEF and physical activity at 84
days following SMB injection were still significantly greater than
those following PBS injection. We consider that LV dimensions
and peak E/A ratio were not necessarily correlated with LVEF
and physical activity, as each parameter was assessed by different
methods individually. However, these findings could suggest
transient effects of cell transplantation on post-MI heart. Further
functional and pathological studies with a longer time period
would clarify this issue.
Although arrhythmogenicity induced by SMB transplantation
remains controversial [1,3,13,25,26], our study provided evidence
for arrhythmia occurrence after SMB transplantation using a rat
model of post-MI chronic HF which is free from anti-arrhythmic
drugs. In the early period, IM injection, but not retrograde IC
injection, of SMB produced a large number of spontaneous VPC
including VT with a peak at day 3. This type of arrhythmias
following IM injection largely disappeared by day 28 and was not
observed following PBS injection. We consider that one of the
causes of this early-phase arrhythmia is local heterogeneity,
geographical and/or biological, generated in the post-MI failing
myocardium. After IM injection, the grafted cells formed isolated,
islet-like clusters in the peri-infarct area, which would cause serious
disorder of the local myocardial structure and electrical conduc-
tance. In addition, these cell-clusters were associated with
accumulation of CD45-positive inflammatory cells, which could
amplify the disorder of myocardial organisation and might also
affect intercellular communication and/or electrical stability of the
surrounding native cardiomyocytes. These pathological events
could lead to generation of ventricular arrhythmias. Retrograde
IC injection, in contrast, disseminated donor-cells widely (without
forming localised cell-clusters) with less inflammation and caused
much less ventricular arrhythmias in the early phase, compared to
IM injection. We recently reported that a similar early-phase
ventricular arrhythmia is caused by IM injection of bone marrow
mononuclear cells [6], suggesting that direct IM cell-injection may
induce arrhythmogenicity in the early period regardless of the cell-
type injected. Similar early-phase arrhythmias have also been
observed in clinical trials of SMB transplantation [1–3], while it
was also reported that prophylactic use of amiodarone [2] and
corticosteroids [3], modifications of the protocol including the
number of cells injected, number of injection sites/volume and use
of human serum for SMB culture are effective in attenuating this
type of arrhythmia [27,28]. For future clinical application of the
IM route for SMB transplantation, however, careful monitoring
and appropriate treatment for the early-phase arrhythmia would
be required.
In the late phase after SMB injection, we found a different type
of arrhythmia occurrence from that in the early phase. There was
a persistent, though not frequent, spontaneous VPC which was
associated with a high risk of VT occurrence under stress as
uncovered by isoproterenol-administration, regardless of the SMB-
delivery route. This finding is consistent to the previous clinical
observation of sustained VT for a long time after IM injection of
SMB [1,3]. We consider that the mechanism for this late-phase
arrhythmia might be different from that in the early phase, as the
local heterogeneity and inflammatory response observed in the
early phase had largely decreased by this time point. Surviving
Figure 4. Survival of grafted cells in the myocardium. Time-
course of donor-derived cell number present in the native LV was
estimated by real-time PCR for the Y-chromosome specific gene, Sry.
Both the SMB-IM and SMB-IC groups showed a small number of donor-
derived cells at day 3, which further decreased by day 28. n= 5 in each
group at each time point.
doi:10.1371/journal.pone.0003071.g004
Figure 5. Size of native cardiomyocytes. The size of native
cardiomyocytes, isolated by enzymatic digestion at day 28 after cell
transplantation, was assessed. Cardiomyocytes in the SMB-IM and SMB-
IC groups were significantly smaller than those in the PBS-IM group, but
still larger than those from the normal hearts. n=5 in the PBS-IM, SMB-
IM and SMB-IC groups; n= 6 in the Normal group. *p,0.05 vs. the
Normal group; {p,0.05 vs. the PBS-IM group.
doi:10.1371/journal.pone.0003071.g005
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Figure 6. Extracellular collagen and capillary density in the myocardium. A: Extracellular collagen deposition in the myocardium was
assessed by Picrosirus red staining at day 28. Representative pictures in the peri-infarct area show a marked accumulation of extracellular collagen
(red colour) in the PBS-IM and PBS-IC groups, compared to the SMB-IM and SMB-IC groups (6400). B: Representative pictures of the infarct-remote
area also show reduced collagen accumulation in the SMB-IM and SMB-IC groups, compared to the PBS-IM and PBS-IC groups (6400). C and D:
Collagen volume in both the peri-infarct and infarct-remote (D) areas, analysed by computer-assisted morphometry, was significantly smaller in the
SMB-IM and SMB-IC groups, compared to the corresponding PBS groups. E: Capillary number at day 28, assessed by immunoconfocal microscopy
(red for vWF, blue for nuclei), appeared to be similar among the groups. F: Capillary density, expressed as the number of capillary vessels per mm2,
did not show a significant difference among any groups. Scale bar = 100 mm. *p,0.05 vs. the PBS-IM group; {p,0.05 vs. the PBS-IC group. N= 5 in
each group.
doi:10.1371/journal.pone.0003071.g006
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grafted cells which acquire arrhythmogenic potential via trans-
differentiation or fusion could be a focus of ventricular
arrhythmias, although such events appeared to be extremely
infrequent [25]. Surviving SMB-derived cells, despite a small
number, might also be a cause of re-entrance arrhythmias. Or, the
native cardiomyocytes might be adversely affected by paracrine
effects of the grafts, leading to arrhythmogenicity. Importantly,
such late-phase arrhythmias were not found following injection of
bone marrow-derived cells via either route into the same animal
model [6], indicating SMB-dependent mechanisms of late-phase
arrhythmias. Further studies for determining the precise mecha-
nism and developing prevention/treatment of the late-phase
arrhythmogenicity following SMB transplantation would be
important for the future clinical success of this therapy.
A possible limitation in our experimental model, in which SMB
derived from GFP-transgenic male SD rat were injected into the
female wild-type SD rat heart, was a host immune response
against allogenicity, Y-chromosome and/or GFP. SD rat is not an
inbred strain in a strict definition, but is very close to inbred.
Actually, it has been successfully used for an organ or cell
transplantation model for heart disease without use of immuno-
depressants [29,30]. These reports have described little immune
response-related inflammation, vasculopathy or organ dysfunction.
Furthermore, GFP-transgenic animals have been frequently used
for a variety of cell therapy models [31], which did not show any
evidence of host-immune response against the GFP. Moreover,
gender mismatched-cell therapy or organ transplantation has been
carried out with few findings of the immune rejection [32,33]. In
addition, the results of our previous experiments using female
immunodeficient rats as a host animal have demonstrated that
such a risk is negligible in our experimental system. Histological
findings, the degree of improvement in cardiac performance
measured by echocardiography, and graft survival measured by
real-time PCR for Sry following transplantation of SMB derived
from male GFP-transgenic SD rats into female wild-type SD rats
were identical to those when the same cells were injected to female
immunodeficient rats (data not shown). These findings suggest that
the host immune response against allogenicity, GFP or Y-
chromosome does not induce inflammation or impair the
fundamental behaviour of the grafted cells and consequent
therapeutic outcomes.
In summary, we have demonstrated that retrograde IC injection
of SMB was able to provide similar, or possibly greater,
therapeutic benefits in treating ischaemic cardiomyopathy with
less arrhythmogenicity in the early phase, compared to direct IM
injection. This data demonstrates the promising utility of the
retrograde IC route for SMB transplantation to treat post-MI
chronic HF. Persistent arrhythmogenicity in the late phase
remains a concern of SMB transplantation regardless of the
delivery-route.
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